The Society for Laboratory Automation and Screening (SLAS) has partnered with two scientific conferences to offer content in Europe this autumn - ELRIG Drug Discovery 2011 and Miptec.
SLAS is sponsoring the Assay Development and Screening session at Drug Discovery 2011, hosted by the European Laboratory Robotics Interest Group (ELRIG), on 7-8 September at the Manchester Central Convention Complex, Manchester, UK.
In this session, chaired by Jeff Paslay, SLAS director, and Richard Eglen, the following companies will emphasise the issues faced when integrating techniques with existing HTS approaches: Stuart Baddeley, Glaxosmithkline; Gary Clark, Biofocus; Ulrich Hassiepen, Novartis; Stephen Rees, Astrazeneca; Frank Stuhmeier, Pfizer; Paul van Midwoud, ETH Zurich.
SLAS is also sponsoring the Drug Discovery Technology session at Miptec on 20-22 September at the Congress Center, Basel, Switzerland.
The session, co-chaired by SLAS member Al Kolb, will educate attendees about the early-stage and future products, and techniques under development at research institutes and young technology companies, and will feature enlightening presentations by the following experts: Janos Voros, Swiss Federal Institute of Technology; Roland Zengerle, University of Freiburg; Christoph Riethmuller, Center for Nanotechnology; Karl Stefansson, Decode Genetics; Robert Brown, University College London; Stefan Przyborski, Durham University; Jens Kelm, Insphero; Phillip Lee, Cellasic; Akwasi Minta, TEF Labs; Sabrina Desbordes, Center for Genomic Regulation; and Johannes Ottl, Novartis Pharma.
